Apalutamide-13C,d3

Apalutamide-13C,d3

• UNSPSC Description: Apalutamide-13C,d3 is the 13C- and deuterium labeled Apalutamide. Apalutamide (ARN-509) is a potent and competitive androgen receptor (AR) antagonist, binding AR with an IC50 of 16 nM[1].
• Target Antigen: Androgen Receptor; Isotope-Labeled Compounds
• Type: Isotope-Labeled Compounds
• Related Pathways: Others;Vitamin D Related/Nuclear Receptor
• Applications: Cancer-programmed cell death
• Field of Research: Cancer
• Solubility: DMSO : 50 mg/mL (ultrasonic;warming)
• Smiles: O=C(N[13C]([2H])([2H])[2H])C1=CC=C(N(C(N(C2=CC(C(F)(F)F)=C(C#N)N=C2)C3=O)=S)C43CCC4)C=C1F
• Molecular Weight: 481.45
• References & Citations: [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-223.|[2]Clegg NJ, et al. ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res. 2012 Mar 15;72(6):1494-503.|[3]Smith MR, et al. Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort. Eur Urol. 2016 May 6. pii: S0302-2838(16)30133
• Shipping Conditions: Blue Ice
• Clinical Information: No Development Reported